Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities

BACKGROUND: Five-year survival rates among stage IIIA lung cancer patients range between 2% and 15%, and there is currently no consensus regarding optimal treatment approaches for these patients. The current investigation evaluated survival outcomes among stage IIIA lung cancer patients receiving 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilfinger, Thomas, Keresztes, Roger, Albano, Denise, Nemesure, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2016
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017688/
https://www.ncbi.nlm.nih.gov/pubmed/27442604
http://dx.doi.org/10.12659/MSM.898675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017688/
https://www.ncbi.nlm.nih.gov/pubmed/27442604
http://dx.doi.org/10.12659/MSM.898675

Ejemplares similares